Taiwanese biopharmaceutical company Golden Biotechnology Corp. on Wednesday released positive interim unblinded data from the Phase 2 clinical trial of its oral investigational new drug for COVID-19 Antroquinonol, and announced it plans to apply for Emergency Use Authorization (EUA) in the United States in April.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Society
Taiwan headline news
12/18/2025 10:35 AM - Business
Taiwan shares open lower
12/18/2025 09:16 AM - Society
2 men detained in 2023 Nantou murder case
12/17/2025 09:10 PM - Cross-Strait
Russia could support China attack on Taiwan: Taiwan security chief
12/17/2025 08:47 PM - Society
Record 13.8 tons of illegal drugs seized in 2025: CGA
12/17/2025 08:01 PM